Display options
Cite
Arora L, Mohan CD, Yang MH, et al. Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers (Basel). 2021;13(21)doi: 10.3390/cancers13215479.
Arora, L., Mohan, C. D., Yang, M. H., Rangappa, S., Deivasigamani, A., Kumar, A. P., Kunnumakkara, A. B., Garg, M., Chinnathambi, A., Alharbi, S. A., Alahmadi, T. A., Rangappa, K. S., Hui, K. M., Sethi, G., & Ahn, K. S. (2021). Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers, 13(21), . https://doi.org/10.3390/cancers13215479
Arora, Loukik, et al. "Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway." Cancers vol. 13,21 (2021). doi: https://doi.org/10.3390/cancers13215479
Arora L, Mohan CD, Yang MH, Rangappa S, Deivasigamani A, Kumar AP, Kunnumakkara AB, Garg M, Chinnathambi A, Alharbi SA, Alahmadi TA, Rangappa KS, Hui KM, Sethi G, Ahn KS. Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers (Basel). 2021 Oct 31;13(21). doi: 10.3390/cancers13215479. PMID: 34771643; PMCID: PMC8582575.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Oct 31;13(21). doi: 10.3390/cancers13215479.

Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway.

Cancers

Loukik Arora, Chakrabhavi Dhananjaya Mohan, Min Hee Yang, Shobith Rangappa, Amudha Deivasigamani, Alan Prem Kumar, Ajaikumar B Kunnumakkara, Manoj Garg, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Tahani Awad Alahmadi, Kanchugarakoppal S Rangappa, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn

Affiliations

  1. Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.
  2. Department of Studies in Molecular Biology, University of Mysore, Manasagangotri, Mysore 570006, India.
  3. KHU-KIST Department of Converging Science and Technology and Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.
  4. Adichunchanagiri Institute for Molecular Medicine, Adichunchanagiri University, BG Nagara, Nagamangala Taluk 571448, India.
  5. National Cancer Centre, Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, Singapore 169610, Singapore.
  6. Cancer Science Institute of Singapore, and Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
  7. Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 781039, India.
  8. Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Noida 201313, India.
  9. Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
  10. Department of Pediatrics, College of Medicine, King Saud University, King Khalid University Hospital, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
  11. Institution of Excellence, Vijnana Bhavan, University of Mysore, Manasagangotri, Mysore 570006, India.

PMID: 34771643 PMCID: PMC8582575 DOI: 10.3390/cancers13215479

Abstract

STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human malignancies, including hepatocellular carcinoma (HCC) and multiple myeloma (MM). Here, we have investigated the action of Tris(dibenzylideneacetone) dipalladium 0 (Tris DBA) on STAT3 signaling in HCC and MM cells. Tris DBA decreased cell viability, increased apoptosis, and inhibited IL-6 induced/constitutive activation of STAT3, JAK1, JAK2, and Src in HCC and MM cells. Tris DBA downmodulated the nuclear translocation of STAT3 and reduced its DNA binding ability. It upregulated the expression of SHP2 (protein and mRNA) to induce STAT3 dephosphorylation, and the inhibition of SHP2 reversed this effect. Tris DBA downregulated the expression of STAT3-driven genes, suppressed cell migration/invasion. Tris DBA significantly inhibited tumor growth in xenograft MM and orthotopic HCC preclinical mice models with a reduction in the expression of various prosurvival biomarkers in MM tumor tissues without displaying significant toxicity. Overall, Tris DBA functions as a good inhibitor of STAT3 signaling in preclinical HCC and MM models.

Keywords: SHP2; STAT3 signaling inhibitor; Tris DBA; orthotopic; xenograft

References

  1. Front Endocrinol (Lausanne). 2019 Jan 08;9:788 - PubMed
  2. J Carcinog. 2017 May 29;16:1 - PubMed
  3. PLoS One. 2016 Apr 20;11(4):e0153155 - PubMed
  4. J Cell Physiol. 2012 May;227(5):2184-95 - PubMed
  5. Open Access Maced J Med Sci. 2019 Jul 20;7(14):2391-2398 - PubMed
  6. Br J Pharmacol. 2010 Oct;161(3):541-54 - PubMed
  7. Biochimie. 2020 Aug;175:58-68 - PubMed
  8. Oncotarget. 2016 Aug 9;7(32):51569-51580 - PubMed
  9. Phytomedicine. 2019 Mar 1;55:282-292 - PubMed
  10. Mol Cancer. 2014 Mar 21;13:66 - PubMed
  11. IUBMB Life. 2021 Nov;73(11):1348-1362 - PubMed
  12. J Biol Chem. 2008 May 23;283(21):14665-73 - PubMed
  13. Br J Pharmacol. 2013 Oct;170(4):807-21 - PubMed
  14. ACS Omega. 2016 Dec 31;1(6):1412-1424 - PubMed
  15. Front Pharmacol. 2018 Nov 05;9:1125 - PubMed
  16. Biochim Biophys Acta. 2014 Apr;1845(2):136-54 - PubMed
  17. Oncotarget. 2016 Apr 12;7(15):19863-83 - PubMed
  18. Leuk Lymphoma. 2016 Jul;57(7):1677-86 - PubMed
  19. Cancer Cell. 2011 May 17;19(5):629-39 - PubMed
  20. Cancer Lett. 2015 May 1;360(2):280-93 - PubMed
  21. Cancer Lett. 2014 Nov 1;354(1):153-63 - PubMed
  22. Mol Interv. 2011 Feb;11(1):18-26 - PubMed
  23. Semin Cancer Biol. 2021 May 9;: - PubMed
  24. J Res Med Sci. 2019 Oct 25;24:86 - PubMed
  25. Biomolecules. 2019 May 03;9(5): - PubMed
  26. Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188574 - PubMed
  27. Biomolecules. 2019 Dec 13;9(12): - PubMed
  28. Pharmacol Ther. 2016 Jun;162:86-97 - PubMed
  29. Pharmacol Res. 2016 Nov;113(Pt A):600-609 - PubMed
  30. Oncotarget. 2017 Mar 14;8(11):17700-17711 - PubMed
  31. Curr Cancer Drug Targets. 2011 Mar;11(3):239-53 - PubMed
  32. Am J Transl Res. 2009 Feb 28;1(3):283-90 - PubMed
  33. Phytomedicine. 2016 May 15;23(5):566-77 - PubMed
  34. Cancers (Basel). 2018 Sep 13;10(9): - PubMed
  35. Leuk Lymphoma. 2016 Oct;57(10):2409-16 - PubMed
  36. Front Oncol. 2018 Mar 19;8:42 - PubMed
  37. Biochem J. 2015 May 15;468(1):1-15 - PubMed
  38. Antioxid Redox Signal. 2016 Apr 10;24(11):575-89 - PubMed
  39. Cancers (Basel). 2014 Jul 03;6(3):1408-40 - PubMed
  40. Inflammation. 2016 Feb;39(1):269-280 - PubMed
  41. Mol Cancer Ther. 2009 Aug;8(8):2211-20 - PubMed
  42. J Cell Biochem. 2019 Jun;120(6):9787-9798 - PubMed
  43. Oncotarget. 2018 Jan 4;9(16):13060-13067 - PubMed
  44. Biochim Biophys Acta. 2013 Jan;1835(1):46-60 - PubMed
  45. Molecules. 2017 Feb 13;22(2): - PubMed
  46. Semin Cancer Biol. 2020 Apr 20;: - PubMed
  47. Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96 - PubMed
  48. Biomolecules. 2019 Sep 30;9(10): - PubMed
  49. Mol Carcinog. 2015 Oct;54(10):971-85 - PubMed
  50. Cancer Prev Res (Phila). 2012 Apr;5(4):631-43 - PubMed
  51. Br J Pharmacol. 2011 Nov;164(5):1506-21 - PubMed
  52. Cancers (Basel). 2018 Nov 08;10(11): - PubMed
  53. J Pharmacol Exp Ther. 2010 Jul;334(1):285-93 - PubMed
  54. Mol Cancer Res. 2011 Dec;9(12):1658-67 - PubMed
  55. iScience. 2019 May 31;15:360-390 - PubMed
  56. Crit Rev Oncol Hematol. 2015 Mar;93(3):149-58 - PubMed
  57. Cancer Res. 2019 Sep 15;79(18):4679-4688 - PubMed
  58. Med Chem. 2015;11(5):462-72 - PubMed
  59. Cancer Lett. 2018 Feb 1;414:214-221 - PubMed
  60. PLoS One. 2017 Aug 10;12(8):e0182282 - PubMed
  61. Mol Oncol. 2015 Apr;9(4):818-33 - PubMed
  62. Bioorg Med Chem Lett. 2021 Oct 15;50:128332 - PubMed
  63. Oncotarget. 2015 Mar 20;6(8):6386-405 - PubMed
  64. Mol Cancer Res. 2009 Nov;7(11):1854-60 - PubMed
  65. PLoS One. 2014 Sep 30;9(9):e107118 - PubMed
  66. Int J Mol Sci. 2017 Jan 12;18(1): - PubMed
  67. Sci Rep. 2015 Sep 21;5:14195 - PubMed
  68. Front Pharmacol. 2018 May 30;9:531 - PubMed
  69. Target Oncol. 2017 Feb;12(1):1-10 - PubMed
  70. Br J Pharmacol. 2011 May;163(2):283-98 - PubMed
  71. Front Oncol. 2019 Feb 21;9:48 - PubMed
  72. Biochimie. 2021 Mar;182:140-151 - PubMed
  73. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  74. Clin Cancer Res. 2008 Oct 1;14(19):6042-54 - PubMed
  75. Anticancer Res. 2009 Jan;29(1):1-9 - PubMed
  76. Int J Oncol. 2016 Sep;49(3):1221-9 - PubMed
  77. J Biol Chem. 2014 Dec 5;289(49):34296-307 - PubMed
  78. Bioorg Med Chem Lett. 2015 Aug 1;25(15):2931-6 - PubMed
  79. Mol Oncol. 2017 Jan;11(1):28-39 - PubMed
  80. Cancer Lett. 2018 Sep 1;431:123-141 - PubMed
  81. Clin Cancer Res. 2008 Sep 15;14(18):5743-8 - PubMed
  82. Cancer Imaging. 2010 Feb 11;10:20-31 - PubMed
  83. Expert Opin Investig Drugs. 2017 Aug;26(8):883-887 - PubMed
  84. Oncotarget. 2017 Feb 21;8(8):12831-12842 - PubMed
  85. Semin Cancer Biol. 2016 Oct;40-41:35-47 - PubMed
  86. PLoS One. 2016 Aug 09;11(8):e0160125 - PubMed
  87. Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10505-E10514 - PubMed
  88. Redox Biol. 2019 Jul;25:101073 - PubMed

Publication Types